Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metronidazole is a nitroimidazole-class small molecule antibiotic and antiprotozoal agent. It is used to treat a variety of infections caused by anaerobic bacteria and certain protozoa, including trichomoniasis, amebiasis, giardiasis, bacterial vaginosis, pelvic inflammatory disease, pseudomembranous colitis, aspiration pneumonia, intra-abdominal infections, lung abscesses, periodontal disease, oral infections and rosacea. Metronidazole works by diffusing into the cytoplasm of susceptible organisms where it is reduced to active metabolites that disrupt DNA helical structure and cause strand breakage leading to cell death. It does not work against viral infections or aerobic bacteria[1][2][3][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metronidazole.